PRECLINICAL ACTIVITY OF THE ANTIBODY-DRUG CONJUGATE DENINTUZUMAB MAFODOTIN (SGN-CD19A) AGAINST PEDIATRIC ALL XENOGRAFTS

BACKGROUND. Denintuzumab mafodotin (SGN-CD19A) is a CD19-targeting antibody-drug conjugate (ADC), comprising a monoclonal antibody conjugated to the potent cytotoxin monomethyl auristatin F (MMAF). Since denintuzumab mafodotin has previously shown activity against B-cell malignancies in early stage...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pediatr Blood Cancer
Main Authors: Jones, Luke, McCalmont, Hannah, Evans, Kathryn, Mayoh, Chelsea, Kurmasheva, Raushan T., Billups, Catherine A., Houghton, Peter J., Smith, Malcolm A., Lock, Richard B.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6588422/
https://ncbi.nlm.nih.gov/pubmed/31012549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.27765
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados